<DOC>
	<DOCNO>NCT00447915</DOCNO>
	<brief_summary>To evaluate efficacy safety R484iv intravenous intermittent administration patient primary osteoporosis comparison sodium risedronate hydrate ( RIS ) oral administration every day . To evaluate also dose response R484iv .</brief_summary>
	<brief_title>Phase II/III Clinical Study R484iv ( Ibandronic Acid ) Primary Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients fragile bone fracture Patients either study site analysis value bone density lumbar spine , proximal part femur neck femur le 80 % young adult mean ( YAM ) . Patients 1 5 bone fracture 4th thoracic spine ( Th4 ) 4th lumbar spine ( L4 ) Ambulatory Patients disease lower bone volume secondarily ( secondary osteoporosis ) Patients receive least one time oral bisphosphonate preparation within 6 month start administration study drug Patient disorder delay passage food esophagus</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>